Benchmark Lowers Harvard Bioscience (NASDAQ:HBIO) Price Target to $4.50

Harvard Bioscience (NASDAQ:HBIO – Free Report) had its price objective reduced by Benchmark from $5.50 to $4.50 in a report issued on Monday morning,Benzinga reports. They currently have a speculative buy rating on the medical instruments supplier’s stock. Harvard Bioscience Price Performance Shares of NASDAQ:HBIO opened at $0.60 on Monday. Harvard Bioscience has a fifty-two […]

Leave a Reply

Your email address will not be published.

Previous post RLJ Lodging Trust (NYSE:RLJ) Price Target Cut to $12.00 by Analysts at KeyCorp
Next post Proficio Capital Partners LLC Makes New $405,000 Investment in Elanco Animal Health Incorporated (NYSE:ELAN)